Targeting high-normal potassium levels (4.5-5.0 mmol/L) is being evaluated in the POTCAST trial protocol to determine if it reduces malignant arrhythmias and mortality in 1,000 ICD patients.
RCT (n=1,000)
Open-label
1:1
Does targeting high-normal plasma potassium levels (4.5-5.0 mmol/L) reduce the risk of malignant arrhythmia and all-cause death in high-risk patients with cardiovascular disease and an ICD?
The POTCAST trial will determine if actively targeting high-normal plasma potassium levels (4.5-5.0 mmol/L) reduces malignant arrhythmias and mortality in ICD patients.
BACKGROUND: Low plasma potassium (p-K) is associated with increased risk of malignant arrhythmia and observational studies indicate protective effects of p-K in the upper reference level. However, randomized clinical studies are needed to document whether actively increasing p-K to high-normal levels is possible and safe and improves cardiovascular outcomes. OBJECTIVE: To investigate if increased p-K reduces the risk of malignant arrhythmia and all-cause death in high-risk patients with a cardiovascular disease treated with an implantable cardioverter defibrillator (ICD) for primary or secondary preventive causes. Secondly, to investigate whether high-normal p-K levels can be safely reached and maintained using already available medications and potassium-rich dietary guidance. METHODS: This is a prospective, randomized, and open-labelled study enrolling patient at high-risk of malignant arrhythmias. According to sample size calculations, 1,000 patients will be randomized 1:1 to either an investigational regiment that aims to increase and maintain p-K at high-normal levels (4.5-5.0 mmol/L) or to usual standard of care and followed for an expected four years. The trial will run until a total of 291 events have occurred providing an α = 0.05 and 1-β = 0.80. The composite primary endpoint includes ventricular tachycardia >125 bpm lasting >30 seconds, any appropriate ICD-therapy, and all-cause mortality. At present, 739 patients have been randomized. CONCLUSIONS: We present the rationale for the design of the POTCAST trial. The inclusion was initiated 2019 and is expected to be finished 2022. The study will show if easily available treatments to increase p-K may be a new treatment modality to protect against malignant arrythmias.
Winsløw et al. (Mon,) conducted a rct in Cardiovascular disease with an implantable cardioverter defibrillator (ICD) (n=1,000). Targeted high-normal potassium levels vs. Usual standard of care was evaluated on Composite of ventricular tachycardia >125 bpm lasting >30 seconds, any appropriate ICD-therapy, and all-cause mortality. Targeting high-normal potassium levels (4.5-5.0 mmol/L) is being evaluated in the POTCAST trial protocol to determine if it reduces malignant arrhythmias and mortality in 1,000 ICD patients.